Study on How Genetic Differences Affect Nalbuphines Pain Relief After Abdominal and Pelvic Surgery in Adults

What this Trial Is About

Researchers are studying how genetic differences affect the pain relief provided by nalbuphine in adults undergoing certain abdominal and pelvic surgeries. This trial aims to identify genes linked to pain and how they influence nalbuphines effectiveness in postoperative patients, focusing on a Pakistani population to help address opioid use challenges and improve pain management. Participants will receive nalbuphine intravenously during surgery, with doses given at induction and as needed based on heart rate and blood pressure. Standard anesthesia with propofol, atracurium, oxygen, nitrous oxide, and isoflurane will be used. Blood samples will be taken before surgery and after extubation for genetic analysis, focusing on patients with persistent pain or opioid side effects. Pain, sedation, nausea, vomiting, and analgesic needs will be monitored for 24 hours after surgery. Participants will be assessed through vital sign monitoring during surgery and pain and sedation evaluations for 24 hours after. Blood samples will be analyzed genetically to explore links between genes and nalbuphine response. Researchers will measure pain scores as the main outcome and track sedation, nausea, vomiting, and additional pain medication use. The study will follow participants from before surgery through 24 hours postoperatively to understand nalbuphines clinical effects and genetic influences.

Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management